https://www.live-feeds.com/feed/pfizer-bets-on-cancer-and-weight-loss-drugs-in-post-pandemic-second-actContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/pfizer-bets-on-cancer-and-weight-loss-drugs-in-post-pandemic-second-acthttps://www.live-feeds.com/feed/pfizer-bets-on-cancer-and-weight-loss-drugs-in-post-pandemic-second-act#u180485Fri, 06 Nov 2026 08:05:44 +0000Pfizer raised its full-year 2026 earnings and revenue forecasts after beating third-quarter expectations. Stronger performance in newer products, cancer drugs, and Eliquis drove the upward revision, offsetting declines in pandemic-era revenue streams. The company also appointed a company veteran as its new chief financial officer. This financial update highlights a broader strategic pivot as the pharmaceutical giant leans into oncology and an aggressive push into next-generation weight-loss treatments during its post-pandemic second act.Why it mattersThe upward revision reflects a critical tur